8-K: Mangoceuticals Announces Conversion of Series B Preferred Stock into Common Stock

Mangoceuticals reports the conversion of Series B Convertible Preferred Stock into common stock on March 28, 2025.

Summary

• On March 28, 2025, Mangoceuticals, Inc. saw the conversion of Series B Convertible Preferred Stock into common stock.
• A holder converted 260 shares of Series B Preferred Stock (valued at $286,000) into 190,667 shares of common stock at a conversion price of $1.50 per share.
• Another holder converted 74 shares of Series B Preferred Stock (valued at $81,400) into 54,267 shares of common stock at the same conversion price.
• A third holder converted 58 shares of Series B Preferred Stock (valued at $63,800) into 42,533 shares of common stock, also at $1.50 per share.
• The company claims an exemption from registration under Section 3(a)(9) of the Securities Act of 1933 for these issuances.

Sentiment

Score: 5

Explanation: The document is a factual report of a stock conversion, with no inherent positive or negative sentiment. It's a neutral event in the company's financial operations.

Positives

• The conversion of preferred stock into common stock could simplify the company's capital structure.

Negatives

• The conversion of preferred stock into common stock dilutes existing shareholders.

Risks

• The dilution of existing shareholders could negatively impact the stock price.

Future Outlook

No specific future outlook is provided in this document.

Management Comments

• Jacob D. Cohen, Chief Executive Officer, signed the report on behalf of Mangoceuticals, Inc.

Industry Context

This announcement is a routine disclosure related to equity transactions. Many companies use preferred stock to raise capital, and conversions to common stock are a normal part of the lifecycle of these securities.

Comparison to Industry Standards

• Similar conversions of preferred stock to common stock are common among publicly traded companies, especially smaller companies utilizing preferred stock as a financing tool.
• The conversion price of $1.50 per share would need to be compared to the market price of Mangoceuticals' common stock at the time of conversion to assess its favorability to the converting shareholders.

Stakeholder Impact

• Existing shareholders may experience dilution due to the increase in the number of outstanding common shares.

Key Dates

Keywords

conversion, preferred stock, common stock, Mangoceuticals, MGRX, equity, securities